scholarly journals Transurethral bipolar plasmakinetic vapo-enucleation of the prostate: Is it safe for patients on chronic oral anticoagulants and/or platelet aggregation inhibitors?

2017 ◽  
Vol 15 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Waleed El-Shaer ◽  
Ahmed Abou-Taleb ◽  
Wael Kandeel
2020 ◽  
Vol 10 (23) ◽  
pp. 8617
Author(s):  
Oana Suciu ◽  
Bogdan Deleanu ◽  
Horia Haragus ◽  
Teodora Hoinoiu ◽  
Cristina Tudoran ◽  
...  

Background: we aimed to analyze the influence of antithrombotic medication in delaying surgery for fragility hip fractures; Method: a total of 312 consecutive hip fracture cases over 55 years who underwent surgery in our Orthopedic Clinic; Results: of these, 90 patients received chronic antithrombotic medication. There were no differences between the medicated group and controls (n = 222) regarding age, gender, type of fracture and haemoglobin at admittance. However, median time to surgery was significantly longer in the medicated group: 4(3–6) days compared to 2(1–4) (p < 0.0001). By type of medication, time to surgery was: 3(1–4) days for acetylsalicylic acid (n = 44), 6(5.25–7.75) days for clopidogrel (n = 15), 4.5(4–7) days for acenocoumarin (n = 18) and 5(4–7.25) days for novel direct oral anticoagulants (n = 13). The Charlson comorbidity index was significantly higher in the medicated group: 5 [4–5] versus 4 [3–5]. There were no differences in transfusions except for fresh frozen plasma, which was administered more in the medicated patients; Conclusions: the prevalence of platelet aggregation inhibitors and anticoagulant use among fragility hip fracture patients is high, with almost a third using some form of antithrombotic medication. This may significantly lengthen time to surgery.


1997 ◽  
Vol 17 (01) ◽  
pp. 43-48 ◽  
Author(s):  
R. Verhaeghe ◽  
J. Vermylen

1993 ◽  
Vol 41 (9) ◽  
pp. 1604-1607 ◽  
Author(s):  
Kiyomi KAGAWA ◽  
Katsuya TOKURA ◽  
Kiyohisa UCHIDA ◽  
Hisato KAKUSHI ◽  
Tsutomu SHIKE ◽  
...  

2014 ◽  
Vol 10 (38) ◽  
pp. 111 ◽  
Author(s):  
Jing Liao ◽  
Yingzhan Tang ◽  
Chengyu Tan ◽  
Hui Ni ◽  
Xueqin Wu ◽  
...  

1977 ◽  
Author(s):  
R. Zimmermann ◽  
K. Andrassy ◽  
C. Zeltsch ◽  
D. Lange ◽  
F. Hof

Previous studies documented an impairment of haemostasis by synthetic penicillins (Thromb. Haem. 34: 115, 1976) and penicillin (Lancet II : 1039, 1976). Therefore the antithrombotic activity of synthetic penicillin. (carbenicillin)(C) was compared with that of aspirin (ASA), dipyridamole (DIPY) and heparin in 150 rabbits. Thrombus formation was induced by standardized endothelial lesions. The dose of C was adjusted to a 4.2 fold prolongation of bleeding time, similar to that seen in clinical patients. Analysis and composition of thrombi was done by measurement of incorporation of labeled blood elements (51cr labeled platelets, 125J-fibrinogen and 59Fe labeled red cells). The ‘specific thrombus/blood ratio’ with values of 19.1 and 50.9 (51cr) in venous and arterial thrombi evidenced the significance of platelets in this model. In the venous system C reduced formation of thrombi by 43%, ASA by 34%, ASA and DIPY by 55% and heparin by 90%. In the arterial system C inhibited thrombus formation by 89%, ASA by 15%, ASA and DIPY by 46% and heparin by 60%. It is concluded, that C effectively prevents thrombus formation in the arterial system and to lower extent in the venous system. The results prove the importance of platelets in arterial thrombogenesis and the efficacy of platelet aggregation inhibitors in preventing thrombi in the arterial system. In comparison with other known antiplatelet drugs it seems, that C is the most effective platelet aggregation inhibitor to date.


Sign in / Sign up

Export Citation Format

Share Document